 |
|
 |
CBio
CBio Limited is a world class Australian biopharmaceutical company that was established in 2000 to develop and commercialise biological therapeutics. CBio's key focus has been on immune modulation technology and the development of its first product, Chaperonin 10 (Cpn10), a heat shock protein. The immune modulation achieved by Cpn10 indicates the drug has significant potential to become a leading therapeutic for autoimmune and inflammatory conditions such as Multiple Sclerosis, Rheumatoid Arthritis, and transplant rejection.
For further information on CBio Ltd, please visit their website at www.cbio.com.au.
|
|
|
|
